middle.news
Dimerix Gains US IND Sponsorship for Phase 2 AKI Drug DMX-652
8:38am on Monday 17th of August, 2026 AEST
•
Healthcare
Read Story
Dimerix Gains US IND Sponsorship for Phase 2 AKI Drug DMX-652
8:38am on Monday 17th of August, 2026 AEST
Key Points
DMX-652 IND sponsorship transferred from Mission Therapeutics to Dimerix
Phase 2 trial for acute kidney injury planned for second half of 2026
DMX-652 targets mitochondrial enzyme USP30 to protect kidney cells
No approved therapies currently exist for acute kidney injury
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE